The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zarogoulidis, P., Sapalidis K., Kosmidis C., Tsakiridis K., Huang H., Bai C., et al. (2020).  Stents for small airways: current practice.. Expert Rev Respir Med. 14(10), 969-972.
Zarogoulidis, P., Kioumis I., Tsiouda T., Pezirkianidis N., Ritzoulis C., Huang H., et al. (2014).  A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease.. J Nanomedine Biotherapeutic Discov. 4(2), 128.
Zarogoulidis, P., Huang H., Tsiouda T., Sardeli C., Trakada G., Veletza L., et al. (2017).  Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.. Respir Med Case Rep. 22, 283-286.
Zarogoulidis, K., Zarogoulidis P., Darwiche K., Boutsikou E., Machairiotis N., Tsakiridis K., et al. (2013).  Treatment of non-small cell lung cancer (NSCLC).. J Thorac Dis. 5 Suppl 4, S389-96.
Zarogoulidis, P., Alexandropoulou I., Romanidou G., Konstasntinidis T. G., Terzi E., Saridou S., et al. (2011).  Community-acquired pneumonia due to Legionella pneumophila, the utility of PCR, and a review of the antibiotics used.. Int J Gen Med. 4, 15-9.
Zarogoulidis, P., Yarmus L., & Zarogoulidis K. (2013).  New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer.. Ther Deliv. 4(10), 1221-3.
Zarogoulidis, P., Chinelis P., Athanasiadou A., Tsiouda T., Trakada G., Kallianos A., et al. (2017).  Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.. Respir Med Case Rep. 22, 101-105.
Zarogoulidis, K., Boutsikou E., Zarogoulidis P., Darwiche K., Freitag L., Porpodis K., et al. (2013).  The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis.. Onco Targets Ther. 6, 1493-500.
Zarogoulidis, P., Terzi E., Kouliatsis G., Androuli S., Kontakiotis T., Zaramboucas T., et al. (2011).  Orbital metastases as the first manifestation of lung adenocarcinoma.. Case Rep Ophthalmol. 2(1), 34-8.
Zarogoulidis, P., Hohenforst-Schmidt W., Huang H., Sapalidis K., Kosmidis C., Tryfon S., et al. (2020).  Vapor for lung volume reduction; pros and cons.. Expert Rev Respir Med. 14(12), 1189-1195.
Zarogoulidis, P., Petridis D., Ritzoulis C., Darwiche K., Spyratos D., Huang H., et al. (2013).  Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.. Int J Pharm. 453(2), 480-7.
Zarogoulidis, P., Trakada G., & Zarogoulidis K. (2013).  A chrono-target chemotherapy treatment model for lung cancer treatment.. Ther Deliv. 4(1), 5-8.
Zarogoulidis, P., Kosmidis C., Fyntanidou V., Barmpas A., Koulouris C., Aidoni Z., et al. (2019).  Elastography during convex-probe (endobronchial ultrasound) for optimal biopsy sample and gene identification in non-small-cell lung cancer.. Biomark Med. 13(14), 1153-1156.
Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Sardeli C., Man Y-G., et al. (2018).  Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.. Transl Lung Cancer Res. 7(Suppl 1), S28-S30.
Zarogoulidis, P., Petridis D., Ritzoulis C., Li Q., Huang H., Ning Y., et al. (2013).  Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays' production systems.. Int J Pharm. 458(1), 39-47.
Zarogoulidis, P., Kouliatsis G., Papanas N., Spyratos D., Constantinidis T. C., Kouroumichakis I., et al. (2011).  Long-term respiratory follow-up of H1N1 infection.. Virol J. 8, 319.
Zarogoulidis, P., Darwiche K., Krauss L., Huang H., Zachariadis G. A., Katsavou A., et al. (2013).  Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients.. Future Oncol. 9(9), 1307-13.
Zarogoulidis, P., Katsikogianni F., Tsiouda T., Sakkas A., Katsikogiannis N., & Zarogoulidis K. (2014).  Interleukin-8 and interleukin-17 for cancer.. Cancer Invest. 32(5), 197-205.
Zarogoulidis, P., Porpodis K., Kioumis I., Petridis D., Lampaki S., Spyratos D., et al. (2014).  Experimentation with inhaled bronchodilators and corticosteroids.. Int J Pharm. 461(1-2), 411-8.
Zarogoulidis, P., Kioumis I., Ritzoulis C., Petridis D., Darwiche K., Porpodis K., et al. (2013).  New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.. Int J Pharm. 455(1-2), 182-8.
Zarogoulidis, K., Zarogoulidis P., Darwiche K., Tsakiridis K., Machairiotis N., Kougioumtzi I., et al. (2013).  Malignant pleural effusion and algorithm management.. J Thorac Dis. 5 Suppl 4, S413-9.
Zarogoulidis, P., Christakidis V., Petridis D., Sapalidis K., Kosmidis C., Vagionas A., et al. (2020).  Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination.. Expert Rev Respir Med.
Zarogoulidis, P., Kioumis I., Papanas N., Manika K., Kontakiotis T., Papagianis A., et al. (2012).  The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in non-responding tuberculosis and diabetes mellitus: a case report and review of the literature.. J Chemother. 24(3), 173-7.
Zarogoulidis, P., Kioumis I., Porpodis K., Spyratos D., Tsakiridis K., Huang H., et al. (2013).  Clinical experimentation with aerosol antibiotics: current and future methods of administration.. Drug Des Devel Ther. 7, 1115-34.
Zarogoulidis, P., Orfanidis M., Constadinidis T. C., Eleutheriadou E., Kontakiotis T., Kerenidi T., et al. (2011).  A 26-year-old male with mesothelioma due to asbestos exposure.. Case Rep Med. 2011, 951732.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.